Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase Ib
No new safety concerns coming out of Phase Ib trial desired to move forward Moving to Phase II, triplet needs…
No new safety concerns coming out of Phase Ib trial desired to move forward Moving to Phase II, triplet needs…